GF-TRIPLE 30mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of GF-TRIPLE supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF-TRIPLE30-B241

Key analytical results include:

• Assay Content: 31.52 mg
• Identification – Retention Time: 1.00
• Identification – Spectrum: 999
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

GF-TRIPLE is a synthetic peptide compound studied in controlled laboratory environments investigating complex metabolic hormone signalling and multi-receptor endocrine pathways.

The compound belongs to a class of advanced incretin-related peptide analogues investigated for their interaction with multiple metabolic regulatory receptor systems.

This preparation contains 30 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide structure and stable analytical profile, GF-TRIPLE has become a frequently referenced compound in experimental metabolic signalling and peptide receptor research models.

Compound Overview

GF-TRIPLE is a synthetic peptide analogue designed to interact with several incretin-related receptor systems involved in metabolic regulation.

In biochemical research, hormones such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon participate in interconnected signalling pathways that regulate cellular metabolic communication.

GF-TRIPLE has been investigated in experimental models exploring how peptide analogues interact simultaneously with multiple receptor systems.

These studies allow researchers to examine multi-receptor signalling mechanisms that influence metabolic regulatory networks and endocrine communication pathways.

Historical Background and Scientific Context

Scientific research into incretin hormones expanded significantly during the late twentieth century as advances in molecular biology enabled detailed investigation of endocrine metabolic systems.

Researchers identified several peptide hormones involved in metabolic signalling coordination, including GLP-1, GIP and glucagon.

As peptide engineering techniques progressed, scientists began developing synthetic analogues capable of interacting with multiple signalling pathways simultaneously.

GF-TRIPLE later emerged as one of the experimental compounds used to study multi-receptor incretin signalling systems and complex metabolic regulatory networks.

Mechanistic Focus in Research

Within experimental laboratory environments, GF-TRIPLE is commonly investigated in relation to complex peptide hormone signalling systems.

Research investigations frequently explore the compound in experimental models examining:

• Multi-receptor incretin signalling pathways
• GLP-1 receptor interaction systems
• GIP receptor signalling dynamics
• Glucagon receptor related metabolic pathways
• Peptide hormone interaction networks
• Cellular metabolic signalling systems
• Comparative peptide analogue research

These experimental models allow scientists to investigate molecular signalling mechanisms involved in metabolic regulation and endocrine communication networks.

Research Applications

In controlled research environments, GF-TRIPLE may be utilised in experimental models designed to explore peptide hormone signalling and metabolic regulatory systems.

Examples of research applications include:

• Metabolic signalling pathway research
• Multi-receptor peptide interaction studies
• Cell signalling pathway analysis
• Molecular metabolic regulation studies
• Comparative peptide analogue evaluation
• Biochemical signalling network modelling
• Controlled in vitro metabolic research

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Independently verified by Liquilabs s.r.o. (Czechia)
Validated assay content 31.52 mg
Purity greater than 99.8 percent
Retention time and spectral identity confirmation
Endotoxin levels below 0.001 EU per mg
No detectable microbial contamination
No detectable heavy metals
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.